Blagoev Krastan B, Iordanov Roumen, Zhou Mengxi, Fojo Tito, Bates Susan E
National Science Foundation, Alexandria, VA 22230, USA.
Department of Biophysics, Johns Hopkins University, Baltimore, MD 21218, USA.
Oncotarget. 2021 Jan 5;12(1):15-21. doi: 10.18632/oncotarget.27855.
Most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered. There is evidence that metastases are formed by phenotypically plastic cancer cells with stem-cell like properties. Currently the population structure and growth dynamics of the resulting metastatic tumors is unknown. Here, using scaling analysis of clinical data of tumor burden in patients with metastatic prostate cancer, we show that the drug resistant, metastasis-causing cells (MCC) are capable of producing drug resistant, exponentially growing tumors, responsible for tumor growth as a patient receives different treatments.
大多数转移性癌症在治疗过程中会产生耐药性并持续生长，这是由对所施用疗法无反应的癌细胞亚群驱动的。有证据表明，转移灶是由具有干细胞样特性的表型可塑性癌细胞形成的。目前，由此产生的转移性肿瘤的群体结构和生长动力学尚不清楚。在这里，通过对转移性前列腺癌患者肿瘤负荷的临床数据进行标度分析，我们表明，耐药的、导致转移的细胞（MCC）能够产生耐药的、呈指数生长的肿瘤，在患者接受不同治疗时导致肿瘤生长。
